Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults
NCT01000571 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104
Last updated 2011-10-07
Summary
This study will evaluate the immunogenicity and safety of inactivated H1N1 swine-origin monovalent influenza vaccine in immunocompromised children and young adults.
Conditions
- H1N1 Pandemic Flu
Sponsors & Collaborators
-
St. Jude Children's Research Hospital
lead OTHER
Principal Investigators
-
Hana Hakim, MD · St. Jude Children's Research Hospital
Eligibility
- Min Age
- 6 Months
- Max Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-10-31
- Primary Completion
- 2011-06-30
- Completion
- 2011-06-30
Countries
- United States
Study Locations
More Related Trials
-
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
NCT01776554 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10
NCT00992212 ·Status: COMPLETED ·Phase: PHASE2
-
Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults
NCT00998803 ·Status: COMPLETED
-
A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months
NCT00956046 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
NCT00971906 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)
NCT00973700 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children
NCT00491985 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age
NCT00971542 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years
NCT00956202 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years
NCT00952419 ·Status: COMPLETED ·Phase: PHASE2
-
Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects
NCT01000207 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Immunogenicity and Safety of V70P5 Revaccination Subjects
NCT01210898 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents
NCT01052402 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children
NCT00884182 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants
NCT01494740 ·Status: COMPLETED ·Phase: PHASE2
-
Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month
NCT01040078 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
NCT00841763 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults
NCT01089660 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly
NCT00954798 ·Status: COMPLETED ·Phase: PHASE2
-
A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine
NCT04669691 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics
NCT00336453 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents
NCT00976469 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population
NCT01007201 ·Status: COMPLETED ·Phase: NA
-
The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug）
NCT01551823 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
NCT00972517 ·Status: COMPLETED ·Phase: PHASE3